ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Names New Head Of R&D

by Rick Mullin
August 31, 2015 | APPEARED IN VOLUME 93, ISSUE 34

Bohen
[+]Enlarge
Credit: AstraZeneca
09334-buscon-bohencxd.jpg
Credit: AstraZeneca

AstraZeneca has appointed Sean Bohen as head of global medicines development and chief medical officer. Bohen, a Ph.D. biochemist and physician, will come to the British drug company from Genentech, where he most recently headed early development and led efforts to incorporate diagnostics into clinical trials. AstraZeneca CEO Pascal Soriot notes that Bohen has extensive experience in oncology and immunology, two key areas in the company’s pipeline.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment